Jithma P. Abeykoon

Comparative efficacy and safety of CD19 chimeric antigen receptor T-cell therapy versus CD3/CD20 bispecific antibodies in relapsed/refractory mantle cell lymphoma: a meta-analysis of clinical trials and real-world studies

CD19-directed chimeric antigen receptor T-cell (CAR-T) therapies and CD3/CD20-directed bispecific antibodies (BsAbs) showed high efficacy in relapsed/refractory mantle cell lymphoma, though comparative data are limited. We performed a meta-analysis of clinical trials and real-wor...